Department of Disease Control and Prevention, Pasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Center for Population Health Science, Hanoi University of Public Health, Hanoi, Vietnam.
J Psychoactive Drugs. 2021 Sep-Oct;53(4):355-363. doi: 10.1080/02791072.2020.1871126. Epub 2021 Jan 27.
The objective of this study was to determine the prevalence of amphetamine-type stimulant use and associated factors among methadone maintenance treatment (MMT) patients. In 2018, a cross-sectional study was conducted on 967 MMT patients at two methadone clinics in Ho Chi Minh City that serve Vietnamese patients. Amphetamine-type stimulant use was assessed by rapid urine test and face-to-face interview using the Alcohol, Smoking, Substance Involvement Screening Test (ASSIST) tool. The prevalence of amphetamine-type stimulant use assessed by urine test was 25.4%. According to ASSIST, the prevalence of moderate and high risk amphetamine-type stimulant use was 15.5% and 1.1%, respectively. Amphetamine-type stimulant use and hazardous use were more prevalent in younger patients, having a part-time job, drug injection, having a lower score of self-health assessment, treated with a higher dose of methadone and missing methadone dose in the past 3 months. By contrast, patients who were HIV positive were less likely to use amphetamine-type stimulants. Cannabis and heroin use were significantly associated with amphetamine-type stimulant use (OR = 1.46; 95% CI: 1.38-8.67; and OR = 1.50; CI: 1.04-2.18, respectively) and hazardous use (OR = 4.07; CI: 1.67-9.92; and OR = 2.38; CI: 1.56-3.63, respectively). Screening and interventions are needed to cope with this issue on time, particularly in young patients, having drug injection and concurrent drugs user groups.
本研究旨在确定美沙酮维持治疗(MMT)患者中苯丙胺类兴奋剂的使用情况及其相关因素。2018 年,在胡志明市的两家美沙酮诊所对 967 名美沙酮维持治疗患者进行了横断面研究,这些患者均为越南人。使用尿液检测和酒精、吸烟、物质使用情况筛查测试(ASSIST)工具进行面对面访谈来评估苯丙胺类兴奋剂的使用情况。尿液检测评估的苯丙胺类兴奋剂使用率为 25.4%。根据 ASSIST,中、高度风险苯丙胺类兴奋剂使用率分别为 15.5%和 1.1%。年轻患者、兼职、药物注射、自我健康评估得分较低、接受较高剂量美沙酮治疗和过去 3 个月漏服美沙酮的患者中,苯丙胺类兴奋剂的使用率和危险使用率更高。相比之下,HIV 阳性患者使用苯丙胺类兴奋剂的可能性较小。大麻和海洛因的使用与苯丙胺类兴奋剂的使用(比值比 [OR] = 1.46;95%置信区间 [CI]:1.38-8.67;和 OR = 1.50;CI:1.04-2.18)和危险使用(OR = 4.07;CI:1.67-9.92;和 OR = 2.38;CI:1.56-3.63)显著相关。需要进行筛查和干预,以便及时应对这一问题,特别是在年轻患者、有药物注射和同时使用其他药物的群体中。